SPECTRA  SPCT TESTS OF NEW DRUG NOT ENCOURAGING HANOVER MASS MARCH 16 SPECTRA PHARMACEUTICAL SERVICES INC SAID CURRENT CLINICAL STUDIES OF ITS PROPOSED DRY EYE DRUG TRETINOIN HAVE NOT PRODUCED ENCOURAGING RESULTS BASED ON PRELIMINARY INDICATIONS THE COMPNAY SAID THE TESTS ARE BEING CONDUCTED FOR SUBMISSION TO THE FOOD AND DRUG ADMINISTRATION FOR THE DRUG WHICH HAS THE TRADE NAME LACRAMORE SPECTRA SAID EARLIER STUDIES SHOWING DRAMATIC IMPROVEMENTS IN ISOLATED CASES HAVE STILL OCCURRED HOWEVER THE OVERALL EVALUATION OF A LARGE NUMBER OF PATIENTS WITH DRY EYE SYNDROME DO NOT DEMONSTRATE CONSISTANTLY BENEFICIAL RESULTS IT ADDED SPECTRA SAID IT WILL CONTINUE ITS CURRENT STUDIES WHILE AT THE SAME TIME UNDERTAKING A REVIEW OF THE FEASABILITY OF THE PROPOSED PRODUCT SPECTRA A DEVELOPMENT STAGE COMPANY ALSO SAID IT HAS INTRODUCED ITS FIRST PROPRIETARY PRODUCT A HYO ALLERGENIC NONIIRRITATING CLEANSER FOR THE CLEANING OF EYELIDS AND EYELASHES THE COMPANY SAID IT HAS ALSO BEGUN MARKETING A LINE OF OPHTHALMIC DRUGS   